Eliem Therapeutics, Inc. (NASDAQ:ELYM – Get Free Report)’s stock price traded up 4.9% during trading on Monday . The company traded as high as $11.77 and last traded at $11.44. 858,993 shares were traded during mid-day trading, an increase of 76% from the average session volume of 486,688 shares. The stock had previously closed at $10.91.
Eliem Therapeutics Stock Up 4.9%
The firm has a market capitalization of $340.36 million, a price-to-earnings ratio of -21.58 and a beta of -0.39. The stock has a 50 day moving average of $9.95 and a 200 day moving average of $6.70.
Eliem Therapeutics Company Profile
Eliem Therapeutics, Inc is a clinical?stage biotechnology company focused on the development of novel therapeutics for the treatment of neurological and neuropsychiatric disorders. The company’s scientific approach is centered on proprietary peptide and small?molecule drug candidates designed to modulate central nervous system pathways. By leveraging targeted delivery and receptor?specific activity, Eliem seeks to address unmet medical needs in areas such as pain management, spasticity and other debilitating sequelae of spinal cord injury.
The company’s most advanced program, ELI-200, is being investigated as a potential treatment for spasticity and neuropathic pain associated with spinal cord injury.
See Also
- Five stocks we like better than Eliem Therapeutics
- These 5 Companies Just Made a Massive Bet on Themselves
- 5 Stocks Built to Thrive in a Higher-for-Longer Economy
- RH’s Strong Q1 Still Leaves Investors With One Big Question
- Iran Ceasefire or Not, These 3 Companies Could Win
Receive News & Ratings for Eliem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eliem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
